A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
← catalyst calendarNCT06836609 · readout in 269 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
132estimated
Sites
4
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-28 | actual | When the study began enrolling |
| Primary completion | 2027-05-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Metabolic Dysfunction-Associated Steatohepatitis
Interventions
- Drug: ALN-CIDEB
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events (TEAEs)
measured Up to 48 Weeks
Severity of TEAEs
measured Up to 48 Weeks
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed